A phase III trial to investigate the efficacy and safety of CPC-201 in patients with Alzheimer's disease
Phase of Trial: Phase III
Latest Information Update: 22 Nov 2016
At a glance
- Drugs Donepezil/solifenacin (Primary) ; Donepezil
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- 22 Nov 2016 According to an Allergan media release, the company intends to advance this study in 2017.
- 06 Jun 2016 According to a Chase Pharmaceuticals media release, the company is about to complete the final trial protocol.
- 09 Dec 2015 New trial record